What is HC Wainwright’s Forecast for Geron Q1 Earnings?

Geron Corporation (NASDAQ:GERN) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Geron in a research report issued on Wednesday, November 5th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will earn ($0.04) per share for the quarter. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s Q2 2026 earnings at ($0.03) EPS.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $47.23 million for the quarter, compared to analysts’ expectations of $55.24 million. Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%.

A number of other brokerages also recently issued reports on GERN. Needham & Company LLC dropped their price target on Geron from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday. The Goldman Sachs Group initiated coverage on shares of Geron in a research note on Thursday, July 10th. They issued a “sell” rating and a $1.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a report on Friday, October 31st. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Geron has an average rating of “Hold” and a consensus target price of $3.64.

Geron Price Performance

Geron stock traded down $0.03 during midday trading on Friday, hitting $1.06. 2,352,760 shares of the company’s stock were exchanged, compared to its average volume of 11,199,604. The company has a market cap of $673.11 million, a P/E ratio of -8.12 and a beta of 0.57. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 7.87. The stock has a 50-day moving average price of $1.30 and a two-hundred day moving average price of $1.36. Geron has a 52-week low of $1.04 and a 52-week high of $4.33.

Institutional Trading of Geron

A number of institutional investors have recently made changes to their positions in the stock. Summit X LLC increased its position in shares of Geron by 43.1% in the first quarter. Summit X LLC now owns 547,899 shares of the biopharmaceutical company’s stock valued at $871,000 after acquiring an additional 164,927 shares during the period. Private Advisor Group LLC grew its position in shares of Geron by 78.5% in the 1st quarter. Private Advisor Group LLC now owns 338,597 shares of the biopharmaceutical company’s stock worth $538,000 after buying an additional 148,949 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Geron during the first quarter valued at approximately $63,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Geron by 13.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 170,441 shares of the biopharmaceutical company’s stock valued at $271,000 after acquiring an additional 20,133 shares in the last quarter. Finally, Kazazian Asset Management LLC bought a new stake in Geron in the first quarter valued at $76,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.